INFORMATIVE WEBINAR: CDTI approves new call for grants for R and investment projects to address the COVID-19 health emergency

At IMPULSO, we are pleased to inform you that, within the extraordinary urgent measures that the Government is carrying out to address the economic and social impact of COVID-19, the CDTI has approved an EXTRAORDINARY CALL aimed at granting aid for the financing of research and development (RD) and investment projects for the manufacture of products related to the health emergency caused by the COVID-19 disease.

The budget allocation is 12 million euros, which could be increased subject to availability.

To provide you with further information, we invite you to the informative WEBINAR that we will hold next Friday, May 22, from 10:00 AM to 11:00 AM, in which we will present, in addition to this EXTRAORDINARY CALL, other NEWS and MEASURES that CDTI has been adopting since the beginning of the COVID-19 pandemic.

Last day to register: May 21 at 2:00 PM

The day before the webinar, we will send connection instructions via email to those who have previously registered.

Below, we summarize the main characteristics of the aid in this new call:

BENEFICIARIES

Companies validly constituted (RD and investment projects) and Technology Centers and/or Technological Innovation Support Centers (only for RD projects).

PROJECT TYPES

• Aid for RD PROJECTS will finance research related to COVID-19, including research on vaccines, medicines and treatments, medical devices and hospital and medical equipment, disinfectants, and protective clothing and equipment, as well as relevant process innovations with a view to efficient production of the necessary products.
• Aid for INVESTMENT PROJECTS must facilitate the manufacture of products related to COVID-19. This concept includes medicines (including vaccines) and treatments, their intermediate products, active pharmaceutical ingredients, and raw materials; medical devices, hospital and medical equipment (including ventilators, protective clothing and equipment, and diagnostic tools) and necessary raw materials; disinfectants and their intermediate products and chemical raw materials necessary for their production; and data collection/processing tools.

PROJECT REQUIREMENTS

• Maximum budget: €625,000.
• Duration of RD projects: Starting in 2020 and ending, at the latest, on October 31, 2021.
• Duration of Investment Projects: Maximum duration of 6 months, starting from the date the aid is granted. Starting in 2020 and ending, at the latest, on October 31, 2020.
• If the project started before February 1, 2020, only additional costs related to acceleration efforts or the expansion of the project’s scope incurred as of February 1, 2020 will be eligible.
• Subcontracting maximum: 65% of the total budget, subject to prior authorization. Not permitted with linked companies.

RD AREAS AND COVID-19 RELATED PRODUCTS ELIGIBLE FOR AID UNDER THIS CALL

• Any product, reagent, active ingredient, and/or medicine considered useful in the diagnosis, prognosis, monitoring, prevention (vaccines), and treatment of the COVID-19 disease, as well as necessary raw materials and intermediates.
• Medical devices of all types; medical and hospital equipment; personal protective equipment (protective goggles, masks of any protection level, gloves, gowns…). Any raw material linked to the production of this type of material.
• Disinfectants and hydroalcoholic and sanitizing solutions in general, both for personal and industrial use (for surfaces, spaces, and rooms), as well as their intermediate products and raw materials.
• Tools for the collection, analysis, and processing of data useful in controlling the COVID-19 disease.
• Any other useful product / technology / process in controlling the COVID-19 disease.

ELIGIBLE COSTS

RD Projects:

• Personnel costs: researchers, technicians, and other auxiliary staff (both staff with employment contracts and self-employed partners of the company).
• Contractual research costs: technical knowledge and patents, as well as consultancy and equivalent services intended exclusively for the project (excluding consultancy associated with the management and processing of the requested aid).
• Material costs, consumables, supplies, and similar products.
• Costs related to obtaining, validating, and defending patents and other intangible assets, as well as obtaining conformity assessments or necessary authorizations for the marketing of new and improved vaccines and medicines, medical devices, hospital and medical equipment, disinfectants, and personal protective equipment.
• Costs related to conducting preclinical and clinical trials (trial phases I-IV). Costs relating to phase IV trials will be eligible provided they allow for new scientific or technological advances.

Investment projects:

• Cost of acquiring tangible fixed assets (facilities, machinery, and equipment) and intangible assets (patents, licenses, technical knowledge, or other industrial and intellectual property rights).
• Personnel costs necessary for conducting line testing of the new production facilities.
• External contracting costs (excluding consultancy associated with the management and processing of the requested aid).
• Material costs, supplies, and similar products directly derived from the project.

TYPE AND INTENSITY OF AID

Non-repayable grant of up to 80% of the eligible budget.

Incompatible with other forms of aid.

For an application to be eligible for aid, it must have a final score equal to or higher than 60 points. The evaluation of the projects will be carried out in accordance with the evaluation criteria and weighting set in the call. IMPULSO can help you improve your score so you don’t miss this great opportunity.

SUBMISSION DEADLINE

The deadline for submitting applications: starting from May 11 at 12:00 noon and will end on December 15, 2020 or until funds are exhausted.

11/05/2020